Financial Security Advisor Inc. boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 592.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 66,555 shares of the company’s stock after acquiring an additional 56,937 shares during the quarter. Merck & Co., Inc. comprises 1.4% of Financial Security Advisor Inc.’s investment portfolio, making the stock its 14th biggest holding. Financial Security Advisor Inc.’s holdings in Merck & Co., Inc. were worth $7,060,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in MRK. Brighton Jones LLC lifted its position in Merck & Co., Inc. by 29.5% during the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after acquiring an additional 8,710 shares during the period. Sivia Capital Partners LLC lifted its position in Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after acquiring an additional 3,941 shares during the period. Diversify Advisory Services LLC lifted its position in Merck & Co., Inc. by 94.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock worth $2,590,000 after acquiring an additional 15,636 shares during the period. Diversify Wealth Management LLC lifted its position in Merck & Co., Inc. by 22.2% during the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock worth $3,054,000 after acquiring an additional 6,897 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Merck & Co., Inc. by 111.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock worth $53,918,000 after acquiring an additional 359,356 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.
Merck & Co., Inc. Stock Down 1.8%
MRK opened at $111.36 on Friday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The business has a 50 day simple moving average of $116.00 and a 200-day simple moving average of $109.21. The stock has a market capitalization of $275.03 billion, a P/E ratio of 31.37, a P/E/G ratio of 2.55 and a beta of 0.18. Merck & Co., Inc. has a 12 month low of $74.37 and a 12 month high of $125.14.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on MRK. JPMorgan Chase & Co. increased their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research report on Monday, April 6th. Wall Street Zen cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. UBS Group increased their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Finally, Guggenheim raised their price target on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $128.18.
Read Our Latest Stock Analysis on MRK
Merck & Co., Inc. Profile
Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.
Founded in the late 19th century as the U.S.
Featured Articles
- Five stocks we like better than Merck & Co., Inc.
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
